| 摘要 |
<p>The use is described of [1R-[1 alpha (Z),2 beta ,3 beta ,5 alpha ]]-(+)-7-[5-[[1,1 min -biphenyl)-4-yl]methoxy]-3-hydrox y-2(1-piperidinyl)cyclopentyl]-4-heptenoic acid or a physiologically acceptable salt, solvate or cyclodextrin complex thereof in the manufacture of medicaments for the therapy or prophylaxis of conditions associated with vasoconstriction and/or platelet aggregation in the uteroplacental circulation and/or excessive synthesis of thromboxane A2 in a pregnant female subject.</p> |
